Financial Ratios

VENKAT PHARMA LTD.

NSE : NABSE : 532093ISIN CODE : INE346F01018Industry : Pharmaceuticals & DrugsHouse : Private
BSE3.400 (0 %)
PREV CLOSE ( ) 3.40
OPEN PRICE ( ) 3.72
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 105
TODAY'S LOW / HIGH ( )3.40 3.72
52 WK LOW / HIGH ( ) 3.43.72
NSE
This Company is not listed in NSE
Select year
ParticularsMar2013Mar2012Mar2011Mar2010Mar2005
Operational & Financial Ratios
   Earnings Per Share (Rs)-0.09-0.07-0.13-0.510.48
   CEPS(Rs)-0.06-0.04-0.08-0.431.06
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)-5.09-5.00-4.93-4.8015.09
   Tax Rate(%)0.000.000.00-4.2927.58
Margin Ratios
   Core EBITDA Margin(%)5.30
   EBIT Margin(%)4.57
   Pre Tax Margin(%)0.82
   PAT Margin (%)0.60
   Cash Profit Margin (%)1.32
Performance Ratios
   ROA(%)-0.25-0.20-0.35-1.100.85
   ROE(%)0.000.000.00-11.443.24
   ROCE(%)-0.26-0.24-0.46-1.4810.20
   Asset Turnover(x)0.000.000.000.001.42
   Sales/Fixed Asset(x)0.000.000.000.009.85
   Working Capital/Sales(x)0.000.000.000.002.08
Efficiency Ratios
   Fixed Capital/Sales(x)0.10
   Receivable days160.30
   Inventory Days46.54
   Payable days64.76
Valuation Parameters
   PER(x)0.000.000.000.0066.35
   PCE(x)-43.96-67.54-41.79-11.0630.02
   Price/Book(x)-0.49-0.48-0.68-1.002.11
   Yield(%)0.000.000.000.000.00
   EV/Net Sales(x)0.72
   EV/Core EBITDA(x)-726.97-1165.84-451.11-90.4213.65
   EV/EBIT(x)-464.54-562.82-280.33-76.4015.80
   EV/CE(x)1.151.130.991.020.94
   M Cap / Sales0.40
Growth Ratio
   Net Sales Growth(%)-100.00-23.84
   Core EBITDA Growth(%)-60.9255.7780.75-110.65102.78
   EBIT Growth(%)-21.5743.0673.82-114.59116.67
   PAT Growth(%)-21.3942.8874.84-216.7313.94
   EPS Growth(%)-21.4842.8974.84-205.9713.94
Financial Stability Ratios
   Total Debt/Equity(x)-7.57-7.70-6.59-6.761.78
   Current Ratio(x)12.7712.083.903.852.92
   Quick Ratio(x)11.2510.573.413.372.14
   Interest Cover(x)-204.43-156.40-320.65-1194.761.22
   Total Debt/Mcap(x)15.4216.059.756.780.84

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.